Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.

Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.

Why Weight Loss Drugs May Not Work

While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:

1. Genetic and Hormonal Variability

Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.

2. Underlying Medical Conditions

Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.

3. Unrealistic Expectations

Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.

Why it is Important to Identify Non-responders

For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.

For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.

Alternative Treatment Options

When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:

1. Switching to Another GLP-1 Drug

For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.

2. Use of Older Medications

While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.

3. Lifestyle Changes

Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.

4. Medical Management of Obesity

It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.

Why Side Effects of Weight Loss Drug Ozempic May Be a Barrier

For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.

Long-term effects of Ozempic or Wegovy on the Brain

Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.

This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.

While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.

The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.

A newly recognised form of diabetes is reshaping how scientists and doctors view the condition, particularly in countries like India. In 2025, global health authorities officially acknowledged Type 5 diabetes as a separate and distinct form of the disease.

This recognition ended decades of confusion around a type of diabetes that did not fit neatly into the existing categories of Type 1 or Type 2 diabetes. The formal classification, backed by the International Diabetes Federation and supported by research published in The Lancet Global Health, is expected to transform diagnosis, treatment, and long-term care for millions of people worldwide.

But what exactly is Type 5 diabetes, and how does it differ from the types of diabetes that are more widely known?

What Is Type 5 Diabetes?

Type 5 diabetes is now recognised as a distinct form of the disease caused primarily by severe, long-term malnutrition, often experienced during childhood. This undernutrition can lead to profound insulin deficiency and an underdeveloped pancreas, resulting in significantly reduced insulin production.

Unlike Type 1 diabetes, which is autoimmune, or Type 2 diabetes, which is linked to insulin resistance, Type 5 diabetes arises from nutritional deficiencies that impair the pancreas’s ability to function properly.

It most commonly affects lean young adults in low-income regions. For years, people with this condition were misdiagnosed as having Type 1 diabetes or an unusual form of Type 2, often leading to inappropriate treatments that failed to address the root cause.

Type 5 Diabetes Symptoms

Symptoms of type 5 diabetes can resemble those seen in other forms of diabetes, such as excessive thirst, frequent urination, persistent tiredness, unexplained weight loss, blurred vision, and slow-healing wounds. However, they are often paired with indications of malnutrition, including a lean physique, delayed growth or puberty in young people, anemia, and recurring infections.

These arise from nutritional deficiencies during early life rather than solely from insulin resistance or autoimmune causes, and they usually present before the age of 30, according to the International Diabetes Federation.

Type 5 Diabetes: Scientists Demand Recognition

Researchers have been studying this condition for decades, particularly in parts of Asia and Africa. Yet, without official recognition, the disease remained poorly understood, and patients were rarely diagnosed correctly. Experts argued that grouping these patients under existing categories obscured the true cause of their illness.

The 2025 classification now formally separates Type 5 diabetes from other types, making it easier to study, identify, and manage. In India, where diabetes prevalence is already high, this recognition is particularly relevant. Tens of millions of people live with diabetes in the country, many of whom remain undiagnosed. Type 5 diabetes highlights a different pattern: it develops not from excess calories, but from too little nutrition during childhood, creating a double burden in regions where obesity and undernutrition coexist.

Implications for Diagnosis and Care

Although there is no new treatment specifically for Type 5 diabetes yet, official recognition marks a major step forward. Doctors can now approach lean patients with a history of malnutrition more carefully, avoiding a “one-size-fits-all” approach. Clearer classification could lead to better guidelines, more personalised care, fewer complications, and improved long-term outcomes.

Experts believe that understanding the role of childhood undernutrition in diabetes could eventually reshape how we prevent, monitor, and manage the condition—something countries like India urgently need as diabetes numbers continue to rise.

An early sign of dementia can sometimes look like a common winter-related issue. When this symptom appears along with other warning signals, it may be wise to speak to a doctor. Dementia is a syndrome marked by a collection of related symptoms that point to a gradual decline in brain function. Over time, this can affect memory, behaviour, thinking, and even movement. In its early phase, however, dementia often shows up through subtle changes that are easy to overlook or mistake for something less serious.

This Common Cold Like Symptom Might Actually Be An Early Sign of Dementia

Dementia UK notes that one possible early indicator of dementia is “low mood, anxiety or depression”. Its specialists explain: “In the early stages of dementia, people often begin to notice symptoms that interfere with day-to-day life.” The difficulty is that low mood or depression can also be linked to seasonal affective disorder (SAD), a form of depression that tends to appear during winter and ease as the days become longer and brighter.

Symptoms of Seasonal Affective Disorder (SAD)

The NHS lists the following possible symptoms of SAD:

• Low mood
• Loss of interest in activities you usually enjoy
• Feelings of guilt, hopelessness or worthlessness
• Feeling restless, tense or easily irritated
• Problems with concentration
• Increased appetite and eating more than usual
• Feeling very tired and sleeping more than usual
• Thoughts of suicide or self-harm

Dementia Early Symptoms

• Problems with memory and concentration
• Difficulties with language and communication, such as struggling to find words or follow conversations
• Difficulties with planning, problem-solving and making decisions
• Getting lost in familiar places because of problems with orientation and reduced ability to recognise usual cues, such as signs or landmarks
• Changes in behaviour and personality, such as becoming more withdrawn or less patient

How Early Symptoms May Differ Between Dementia Types

The organisation explains: “A person experiencing early symptoms of dementia may notice these changes themselves, or they may be picked up first by family members, friends or colleagues. Memory problems are not always obvious in the early stages of some types of dementia, such as frontotemporal dementia, where changes in behaviour and personality may appear first.

“People with young onset dementia, where symptoms begin before the age of 65, are also less likely to have memory loss as an early symptom.”

Emotional Changes Linked To Specific Forms Of Dementia

The charity also points out that emotional changes can be linked to two specific types of dementia. In vascular dementia, a person may experience “changes in mood, behaviour and personality”, while Lewy body dementia can cause “mood changes, including anxiety and depression”.

Dementia: Why These Symptoms Can Be Hard To Identify

That said, it is often difficult to know at first whether dementia is the cause of these warning signs. Dementia UK advises: “Many symptoms associated with dementia can also be caused by other physical or mental health conditions, such as thyroid disorders, menopause, vitamin B12 deficiency, depression, anxiety, work-related stress or relationship difficulties.

“This means that experiencing symptoms linked to dementia does not automatically mean someone has the condition. However, if you or someone close to you is showing signs or symptoms of dementia, it is important to visit a GP to understand what might be causing them.”

When To Seek Medical Advice

If you or someone you know is showing symptoms that resemble dementia, seeking advice from your GP is an important first step.

Gonorrhea poses a far more serious challenge than many realise. Over the years, doctors treating the infection have seen their treatment choices steadily shrink. The bacteria responsible, Neisseria gonorrhoeae, has repeatedly adapted to antibiotics, rendering many once-reliable drugs ineffective. As a result, clinicians have been forced to depend heavily on a single injectable medication, a situation that has raised growing concern.

That dependence is becoming increasingly risky. Data from the US Centers for Disease Control and Prevention show that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90% since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.

FDA Clears First New Gonorrhea Drug In 30 Years

This month, however, marked a significant shift. The US Food and Drug Administration approved two new oral antibiotics to treat gonorrhea: zoliflodacin and gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.

“These approvals mark a significant milestone for treatment options for patients with uncomplicated urogenital gonorrhea,” said Dr Adam Sherwat of the FDA in an official statement.

Why Gonorrhea Has Become Harder to Treat

If left untreated, gonorrhea can lead to serious complications, including pelvic inflammatory disease, infertility, and in rare cases, infections that spread to the joints or bloodstream, as per Cleveland Clinic. Many people experience no symptoms at all, allowing the infection to spread quietly. Despite years of research, there is still no licensed vaccine, leaving antibiotics as the primary line of defence.

What the FDA’s Decision Changes

The newly approved treatments offer a fresh sense of hope. Zoliflodacin, developed by the nonprofit Global Antibiotic Research and Development Partnership in collaboration with Innoviva Specialty Therapeutics, is designed as a single-dose oral medication. Gepotidacin, developed by GSK, is taken in two doses and is also approved for treating certain urinary tract infections.

Both medicines eliminate the need for injections, a shift that could make treatment simpler and more accessible, particularly in settings where access to clinics is limited.

FDA Clears First New Gonorrhea Drug: How the Two New Medicines Work

As per Medscape, clinical trial results for both drugs have been encouraging. Zoliflodacin was tested in a large international study involving more than 900 participants across Europe, Africa, Asia, and the US. The drug successfully cured about 90.9% of patients, a rate comparable to the 96.2% success rate of the current injectable standard. Most reported side effects were mild.

Gepotidacin showed similarly strong results in a separate Phase 3 trial that included around 600 patients from six countries. The cure rate reached 92.6%. Some participants reported digestive issues, but these effects were generally described as mild.

What the Trial Results Show

Importantly, both medications were effective against strains of gonorrhea that no longer respond to older antibiotics. That said, public health experts stress that these drugs are not a permanent solution.

“Bacteria are smart. They can pass resistant mechanisms between each other,” said Dr Manica Balasegaram of the Global Antibiotic Research and Development Partnership, speaking to CNN.

Why Experts Say Caution Is Still Needed

Several uncertainties remain. Neither drug has yet shown strong effectiveness against throat infections, known as pharyngeal gonorrhea, which are more difficult to detect and treat. There is also ongoing debate about how best to use the new medications. Some experts argue they should be reserved as last-line treatments, while others believe earlier use could help slow resistance.

Dr Tereza Kasaeva of the World Health Organization described the approvals as “an important and timely development” amid rising global infection rates and limited treatment options, according to The Guardian.

For now, the new drugs provide much-needed breathing room. Whether that progress holds will depend on careful prescribing and close monitoring of how resistance evolves.